Skip to main content
Premium Trial:

Request an Annual Quote

Charles Harwood, Tim Derrington, John Sluis, John Fazio

BioReliance has named Charles Harwood, who currently is executive chairman, to the post of interim CEO in the wake of the departure of former CEO Tim Derrington.
 
BioReliance, which Invitrogen sold in April to Avista Capital Partners for $210 million, noted that since June three senior executives have joined the company, including David Onions as CSO, David Walker as CFO, and Darryl Goss as VP of Global Process Excellence.
 
Harwood formerly was president and CEO of Focus Diagnostics and was SVP of venture development at Covance.
 

 
Cepheid CFO John Sluis will retire on Dec. 31, the company said in its quarterly earnings statement this week. The company is seeking a replacement for Sluis, who will remain a consultant for Cepheid through 2008. Sluis joined Cepheid as VP of finance and CFO.
 

 

Sequenom has appointed John Fazio to its board of directors. Fazio, who also will serve as chairman of the firm’s audit committee, formerly was senior general practice partner at PricewaterhouseCoopers, where he had a 35-year career.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.